In an international multicenter cohort of 4,302 individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and high blood pressure, renin–angiotensin system inhibitor (RASi) and calcium channel blocker (CCB) use was associated with more favorable liver outcomes and a lower risk of long-term liver-related events (LREs). Over a median follow-up of 4.6 years, RASi use was associated with a greater likelihood of liver stiffness regression (HR 1.220) and a substantially lower risk of LREs (HR 0.431), without a significant association with liver stiffness progression. In contrast, CCB use was associated with a lower risk of liver stiffness progression (HR 0.681) and LREs (HR 0.559), but not with liver stiffness regression. These findings suggest that both RASi and CCBs may have beneficial liver-related effects in people with MASLD and high blood pressure, although their associations with liver stiffness trajectories appear to differ. Source: https://www.cghjournal.org/
